Business
Director dealings
Director dealings.
About this update from Hvivo Plc
[{"type":"text","content":"\n\n\nhVIVO plc\n(\"hVIVO\" or the \"Company\")\n \nDirector dealings\n \nhVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) announces that it has received notification that Yamin 'Mo' Khan, Chief Executive Officer of the Company, yesterday acquired 13,526 ordinary shares of 0.1 pence each in the capital of the Company as a result of a dividend reinvestment plan. Following the purchase of shares Mo holds 523,730 ordinary shares representing approximately 0.08 per cent of the Company's issued ordinary capital.\n \nFor further information please contact:\n \n\n\n\n\nhVIVO plc\n\n\n+44 (0) 20 7756 1300\n\n\n\n\nYamin 'Mo' Khan, Chief Executive Officer\nStephen Pinkerton, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLiberum Capital (Nominated Adviser and Joint Broker)\n\n\n +44 (0) 20 3100 2000\n\n\n\n\nBen Cryer, Edward Mansfield, Phil Walker, Will King\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nfinnCap plc (Joint Broker)\n\n\n+44 (0) 20 7220 0500\n\n\n\n\nGeoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDavy (Euronext Growth Adviser and Joint Broker)\n\n\n+353 (0) 1 679 6363\n\n\n\n\nAnthony Farrell, Niall Gilchrist\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Financial PR & IR)\nStephanie Cuthbert / Phillip Marriage /\nLouis Ashe-Jepson\n\n\n+44 (0) 20 7933 8780 or [email protected]\n+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /\n+44 (0) 7747 515 393\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors\n \nAbout hVIVO\n \nhVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.\n \nThe Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a...